!!Per Svenningsson - Publications
\\
361 publications (PubMed),16024 citations, H index 69 (Web of Science)\\
\\
__Ten representative papers__\\
\\
1: Lazarevic V, Yang Y, Flais I, Svenningsson P. Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors. Mol Psychiatry. 2021 Dec;26(12):7425-7435. doi: 10.1038/s41380-021-01246-3. \\
\\
2: Simone R, Javad F, Emmett W, Wilkins OG, Almeida FL, Barahona-Torres N, Zareba-Paslawska J, Ehteramyan M, Zuccotti P, Modelska A, Siva K, Virdi GS, Mitchell JS, Harley J, Kay VA, Hondhamuni G, Trabzuni D, Ryten M, Wray S, Preza E, Kia DA, Pittman A, Ferrari R, Manzoni C, Lees A, Hardy JA, Denti MA, Quattrone A, Patani R, Svenningsson P, Warner TT, Plagnol V, Ule J, de Silva R. MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration. Nature. 2021 Jun;594(7861):117-123. doi: 10.1038/s41586-021-03556-6. \\
\\
3: Markaki I, Ntetsika T, Sorjonen K, Svenningsson P; BioPark Study Group. Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease. Mov Disord. 2021 Jun;36(6):1430-1434. doi: 10.1002/mds.28545. \\
\\
4: Mantas I, Vallianatou T, Yang Y, Shariatgorji M, Kalomoiri M, Fridjonsdottir E, Millan MJ, Zhang X, Andrén PE, Svenningsson P. TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition. Biol Psychiatry. 2021 Jul 1;90(1):16-27. doi: 10.1016/j.biopsych.2020.12.008. \\
\\
5: Sousa VC, Mantas I, Stroth N, Hager T, Pereira M, Jiang H, Jabre S, Paslawski W, Stiedl O, Svenningsson P. P11 deficiency increases stress reactivity along with HPA axis and autonomic hyperresponsiveness. Mol Psychiatry. 2021 Jul;26(7):3253-3265. doi: 10.1038/s41380-020-00887-0. \\
\\
6: Laffita-Mesa JM, Nennesmo I, Paucar M, Svenningsson P. A Novel Duplication in ATXN2 as Modifier for Spinocerebellar Ataxia 3 (SCA3) and C9ORF72-ALS. Mov Disord. 2021 Feb;36(2):508-514. doi: 10.1002/mds.28334. \\
\\
7: Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J; IRL752 Collaborators. A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia. Mov Disord. 2020 Jun;35(6):1046-1054. doi: 10.1002/mds.28020. \\
\\
8: Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P. α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235. doi: 10.1073/pnas.1821409116\\
\\
9: Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science. 2003 Nov 21;302(5649):1412-5. doi: 10.1126/science.1089681.\\
\\
10: Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science. 2006 Jan 6;311(5757):77-80. doi: 10.1126/science.1117571.